The payment was triggered by utilization of previous cash balances, reflecting progress in the trial. The cash payment will be included in Vical’s year-end 2007 cash balances, consistent with the company’s guidance of a projected 2007 net cash burn of $27 million to $32 million.
Vical is conducting the trial in accordance with a special protocol assessment completed with the FDA.